Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
Type:
Grant
Filed:
December 29, 2022
Date of Patent:
April 2, 2024
Assignee:
Biomea Fusion, Inc.
Inventors:
David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
Type:
Grant
Filed:
September 10, 2021
Date of Patent:
December 19, 2023
Assignee:
Biomea Fusion, Inc.
Inventors:
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 31, 2019
Date of Patent:
November 16, 2021
Assignee:
BIOMEA FUSION, INC.
Inventors:
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter